Survival among adolescents and young adults with cancer in Germany and the United States: An international comparison

Abstract

Serious concern arose in the scientific literature about the state of and progress in cancer survival among adolescent and young adult (AYA) patients in the recent years. We provide an up-to-date international comparison of survival among AYA patients. Using population-based cancer data from 11 German cancer registries and the SEER Program of the United States (covering populations of 39 and 33 million people, respectively), standardized tumor group classifications, period analysis and modeling, we compared the 5-year relative survival of AYA patients in the age groups 15-29 and 30-39 to survival seen among adults aged 40-49 for the 2002-2006 period. Additionally, we also provide an age-specific survival comparison between the two countries. In 2002-2006, for the overwhelming majority of the more than 30 types of cancer examined, AYA patients aged both 15-29 and 30-39 years had higher or similar survival than patients in the age group 40-49 in both countries. A numerically large and statistically significant survival deficit among AYA patients was only found for breast carcinomas in both populations, and colorectal and stomach carcinoma in the United States for the age group 15-29. Overall, results of the country-specific comparisons did not indicate systematic differences. With very few exceptions, no survival deficit between AYA patients and adults aged 40-49 years was found in either of the examined countries in the first decade of the 21st century. What's new? Meeting the needs of adolescent and young adult (AYA) cancer patients is a vital yet challenging area of cancer care, one that has received increased attention due to slow gains in patient survival. Here, comparison of 5-year survival in Germany and the United States reveals similar or better survival for AYA patients compared with adult patients. Progress in AYA survival may be attributed to various factors, including increased clinical trial participation and improved access to insurance. The findings could help direct future care policy for this special patient population. © 2013 UICC.